Crinetics Pharmaceuticals: Relating To The Private Placement Is Hereby Incorporated By Reference Into This Item 3.02. Based In Part Upon The Representations Of The Purchasers In The Securities Purchase Agreement, The Offering And Sale Of The Securities Was Made In Reliance On The Exemption Afforded By Regulation D Under The Securities Act Of 1933, As Amended (the Securities Act ), And Corresponding Provisions Of State Securities Or Blue Sky Laws. The Offer And Sale Of The Shares Issued In The Private Placement Have Not Been Registered Under The Securities Act Or Any State Securities Laws And Such Shares May Not Be Offered Or Sold In The United States Absent Registration With The Sec Or An Applicable Exemption From The Registration Requirements. The Sale Of The Shares In The Private Placement Did Not Involve A Public Offering And Was Made Without General Solicitation Or General Advertising. The Purchasers Represented In The Securities Purchase Agreement That They Are Accredited Investors, As Such Term Is Defined In Rule 501(a) Of Regulation D Under The Securities Act, And That They Are Acquiring The Securities Not With A View To Any Resale, Distribution Or Other Disposition Of The Securities In Violation Of The U.s. Federal Securities Laws, Other Events, Financial Statements And Exhibits

Show full article

This functionality is available for registred users only

• Full name
  Crinetics Pharmaceuticals, Inc.
• Registration country
  USA
• Industry
  Pharmaceutical Preparation and Biotechnology
• М/S&P/F
  *** / *** / ***